Bone mineral density loss on long-term androgen-deprivation therapy (ADT) for the prostate cancer patients in Japan

Bone mineral density loss on long-term androgen-deprivation therapy (ADT) for the prostate cancer patients in Japan

Bibliographic Details
Main Authors:	Yu Ogawa, Yuuki Matsui, Takehiko Nakasato, Kazuhiko Oshinomi, Jun Morita, Michio Naoe, Kozo Fuji, Yoshio Ogawa
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-06-01
Series:	Urological Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S1879522615000809

Similar Items

Treatment strategy for prostatic abscess: Eighteen cases' report and review of literature
by: Kazuhiko Oshinomi, et al.
Published: (2018-01-01)

New circulating tumor cells (CTCs) evaluation method in prostate cancer
by: Takehiko Nakasato, et al.
Published: (2016-06-01)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
by: Tobias Engel Ayer Botrel, et al.
Published: (2016-01-01)

Increasing the age of brain: Effect of Androgen Deprivation Therapy (ADT) exposure on brain and cognition
by: A.C. Plata Bello, et al.
Published: (2020-07-01)

Indications for ureteropyeloscopy in the detection of upper urinary tract tumors
by: Jun Morita, et al.
Published: (2018-01-01)

A Novel, Circulating Tumor Cell Enrichment Method Reduces ARv7 False Positivity in Patients with Castration-Resistant Prostate Cancer
by: Takehiko Nakasato, et al.
Published: (2020-03-01)

Surgical challenges of Castleman's disease of the pelvis
by: Sat Prasad Nepal, et al.
Published: (2021-01-01)

The effect on quality of life of androgen deprivation therapy (ADT) combined with local external prostate radiotherapy in patients with primary metastatic prostate cancer, results from the HORRAD trial
by: L.M.S. Boevé, et al.
Published: (2020-07-01)

346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
by: Christian Poehlein, et al.
Published: (2020-11-01)

ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC) by prior local and systemic treatment
by: A. Stenzl, et al.
Published: (2020-07-01)

Development of a Highly Sensitive Technique for Capturing Renal Cell Cancer Circulating Tumor Cells
by: Michio Naoe, et al.
Published: (2019-08-01)

Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
by: Mayhew Richard G, et al.
Published: (2011-09-01)

De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)
by: Ted A. Skolarus, et al.
Published: (2018-11-01)

Bone mineral density in Nigerian men on androgen deprivation therapy for advanced prostate cancer
by: Olufemi Olayide Ojewuyi, et al.
Published: (2020-08-01)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
by: Katherine Neubecker, et al.
Published: (2011-01-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”
by: Katherine Neubecker, et al.
Published: (2017-01-01)

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
by: Dominick G A Burton, et al.
Published: (2013-01-01)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

A cost-outcome analysis of androgen deprivation therapy and androgen deprivation therapy combine radiotherapy for locally advanced prostate cancer
by: Wei-Na Wang, et al.
Published: (2011)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
by: Rahul Jena
Published: (2020-01-01)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
by: Jui-Ming Liu, et al.
Published: (2020-01-01)

Metabolomic effects of androgen deprivation therapy treatment for prostate cancer
by: Jen‐Tsan Chi, et al.
Published: (2020-06-01)

Transcription factors involved in prostate gland adaptation to androgen deprivation.
by: Rafaela Rosa-Ribeiro, et al.
Published: (2014-01-01)

Androgen deprivation therapy as backbone therapy in the management of prostate cancer
by: Merseburger AS, et al.
Published: (2016-11-01)

An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
by: Kristene Myklak, et al.
Published: (2011-01-01)

Antifracture agents for prostate cancer patients on androgen deprivation therapy
by: Bhupendra P Singh, et al.
Published: (2010-01-01)

Cardiovascular health in men on androgen deprivation therapy for prostate cancer
by: Gilbert, Stephen E.
Published: (2013)

The effect of strength training on muscle cellular stress in prostate cancer patients on ADT
by: T S Nilsen, et al.
Published: (2016-05-01)

Association Between Androgen Deprivation Therapy for Prostate Cancer and Alzheimer's Disease
by: Giannantoni-Ibelli, Gina
Published: (2018)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
by: Uri Amit, et al.
Published: (2019-06-01)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
by: Syed Imran Ali Shah
Published: (2015-01-01)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
by: Julia Lipianskaya, et al.
Published: (2014-08-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes
by: Pietro Enea Lazzerini, et al.
Published: (2020-05-01)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
by: Nicoletta Ferrari, et al.
Published: (2017-12-01)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
by: Mahnaz Roayaei, et al.
Published: (2013-01-01)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
by: Chun-Te Wu, et al.
Published: (2018-12-01)

Cannot write session to /tmp/vufind_sessions/sess_5huhbquh2bkkj153o388g6d5a0